Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
Top Cited Papers
- 28 July 2014
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 64 (5), 485-494
- https://doi.org/10.1016/j.jacc.2014.02.615
Abstract
No abstract availableFunding Information
- Netherlands Organisation for Scientific Research
- Atherotech Diagnostics
- AstraZeneca Pharma U.S., Inc.
- National Heart, Lung, and Blood Institute
- AstraZeneca
- Boehringer Ingelheim Ltd. U.K.
- Eli Lilly and Co., Ltd.
- JRDF
- Pfizer Inc.
- Roche Products Ltd.
- Sanofi-Aventis
This publication has 38 references indexed in Scilit:
- Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection StudyEuropean Heart Journal, 2012
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)European Heart Journal, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) CohortCirculation: Cardiovascular Genetics, 2009
- Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose ResponseCirculation: Cardiovascular Genetics, 2008
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinThe New England Journal of Medicine, 2008
- Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group RecommendationsThe American Journal of Cardiology, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsThe New England Journal of Medicine, 1998